covid-19 disease. covid-19 disease
Conditions
Interventions
Intervention 1: Intervention group: Take tocilizumab. This group is given a dose of 8 mg per kilogram of body weight tocilizumab up to a maximum dose of 800 mg. If the symptoms worsen or do not improv
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: COVID-19 disease confirmed by chest ct and PCR No pregnancy No breastfeeding Negative PPD No bacterial pneumonia (negative sputum and urine culture) Not use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine , Informed consent
Exclusion criteria
Exclusion criteria: Disapproval of covid-19 disease by chest computed tomography and PCR Positive PPD Bacterial pneumonia (negative sputum and urine culture) Pregnancy Breastfeeding Use of atorvastatin , alprazolam , amlodipine , MTX , hydroxychloroquine by the patient Lack of Informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigation of mortality rate of CIVID-19 patients. Timepoint: After treatment. Method of measurement: Situation of the patient's life. | — |
Secondary
| Measure | Time frame |
|---|---|
| The average number of hospitalization days for COVID-19 patients. Timepoint: End of treatment. Method of measurement: Day.;Average platelets count. Timepoint: Before and after treatment. Method of measurement: Complete Blood Count (CBC) test.;Average percentage of oxygen saturation. Timepoint: Every 12 hours. Method of measurement: Puls oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohammadreza Bozorgmanesh
Arak University of Medical Sciences
Outcome results
None listed